|
Solvonis Therapeutics PLC - London-based biopharmaceutical company, focused on central nervous system disorders - Celebrates second US patent by United States Patent & Trademark Office, covering a further monoamine modulator compound series arising from its proprietary post-traumatic stress disorder discovery programme. The patent, U.S. Patent No. 12,595,269, was issued on Tuesday. On March 31, the company had announced the first such patent, U.S. Patent No. 12,590,077. Solvonis Chief Scientific Officer David Nutt says: ‘This second patent reflects the breadth of our monoamine modulation research and the scientific strategy behind it. By exploring multiple chemically distinct series acting across serotonin, dopamine and noradrenaline transporter systems, we increase the probability of identifying differentiated compounds with attractive translational and therapeutic profiles.’ Current stock price: 0.27 pence each, flat on Wednesday afternoon in London 12-month change: up 59% Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
